IP Verse

Methods For Controlling Blood Pharmacokinetics Of Antibodies - EP3056568

The patent EP3056568 was granted to Chugai Seiyaku Kabushiki Kaisha on Sep 15, 2021. The application was originally filed on Mar 30, 2007 under application number EP15196240A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3056568

CHUGAI SEIYAKU KABUSHIKI KAISHA
Application Number
EP15196240A
Filing Date
Mar 30, 2007
Status
Granted And Under Opposition
Aug 13, 2021
Grant Date
Sep 15, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

NOVO NORDISKJun 15, 2022J A KEMPADMISSIBLE
STRAWMANJun 14, 2022PLASSERAUDWITHDRAWN

Patent Citations (30) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONJP20050112514-
DESCRIPTIONEP0125023
DESCRIPTIONEP0239400
DESCRIPTIONJPH0159878B
DESCRIPTIONJPH10504970
DESCRIPTIONWO2005035756
DESCRIPTIONWO9201047
DESCRIPTIONWO9203918
DESCRIPTIONWO9219759
DESCRIPTIONWO9220791
DESCRIPTIONWO9306213
DESCRIPTIONWO9311236
DESCRIPTIONWO9319172
DESCRIPTIONWO9402602
DESCRIPTIONWO9501438
DESCRIPTIONWO9515388
DESCRIPTIONWO9515393
DESCRIPTIONWO9602576
DESCRIPTIONWO9633735
DESCRIPTIONWO9634096
DESCRIPTIONWO9813388
DESCRIPTIONWO9846777
DESCRIPTIONWO9951743
EXAMINATIONUS2006057149
EXAMINATIONWO2005121180
OPPOSITIONEP0329185
OPPOSITIONEP2006381
OPPOSITIONEP3056568
OPPOSITIONUS2005244403
OPPOSITIONWO9803546

Non-Patent Literature (NPL) Citations (81) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ADAMS CW; ALLISON DE; FLAGELLA K; PRESTA L; CLARKE J; DYBDAL N; MCKEEVER K; SLIWKOWSKI MX, "Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab.", CANCER IMMUNOL IMMUNOTHER., (20050903), pages 1 - 11-
DESCRIPTION- AMIT ET AL., SCIENCE, (1986), vol. 233, pages 747 - 53-
DESCRIPTION- CHOTHIA ET AL., J. MOL. BIOL., (1987), vol. 196, pages 901 - 17-
DESCRIPTION- CHOTHIA ET AL., NATURE, (1989), vol. 342, page 877-
DESCRIPTION- CLACKSON ET AL., NATURE, (1991), vol. 352, pages 624 - 8-
DESCRIPTION- COMPER WD; GLASGOW EF., "Charge selectivity in kidney ultrafiltration.", KIDNEY INT., (199505), vol. 47, no. 5, pages 1242 - 51-
DESCRIPTION- COUTO JR; BLANK EW; PETERSON JA; CERIANI RL., "Anti-BA46 monoclonal antibody Mc3: humanization using a novel positional consensus and in vivo and in vitro characterization.", CANCER RES., (19950415), vol. 55, no. 8, pages 1717 - 22, XP000919432-
DESCRIPTION- COX KM ET AL., NAT. BIOTECHNOL., (200612), vol. 24, no. 12, pages 1591 - 1597-
DESCRIPTION- DALL'ACQUA WF, METHODS, (200505), vol. 36, no. 1, pages 43 - 60-
DESCRIPTION- DEEN WM; LAZZARA MJ; MYERS BD., "Structural determinants of glomerular permeability", AM J PHYSIOL RENAL PHYSIOL., (200110), vol. 281, no. 4, pages F579 - 96-
DESCRIPTION- EBERT ET AL., BIO/TECHNOLOGY, (1994), vol. 12, pages 699 - 702-
DESCRIPTION- G. KOHLER; C. MILSTEIN, METHODS ENZYMOL., (1981), vol. 73, pages 3 - 46-
DESCRIPTION- GOBBURU JV; TENHOOR C; ROGGE MC; FRAZIER DE JR; THOMAS D; BENJAMIN C; HESS DM; JUSKO WJ, "Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys", J PHARMACOL EXP THER., (199808), vol. 286, no. 2, pages 925 - 30, XP000989582-
DESCRIPTION- GODING, Monoclonal Antibodies: Principles and Practice, ACADEMIC PRESS, (1986), pages 59 - 103-
DESCRIPTION- GOODE NP; SHIRES M; DAVISON AM, "The glomerular basement membrane charge-selectivity barrier: an oversimplified concept?", NEPHROL DIAL TRANSPLANT., (199609), vol. 11, no. 9, pages 1714 - 6-
DESCRIPTION- GRAVES SS; GOSHORN SC; STONE DM; AXWORTHY DB; RENO JM; BOTTINO B; SEARLE S; HENRY A; PEDERSEN J; REES AR, "Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody", CLIN CANCER RES., (199904), vol. 5, no. 4, pages 899 - 908, XP000941615-
DESCRIPTION- GRIFFITHS ET AL., EMBO J., (1994), vol. 13, pages 3245 - 60-
DESCRIPTION- HE XY; XU Z; MELROSE J; MULLOWNEY A; VASQUEZ M; QUEEN C; VEXLER V; KLINGBEIL C; CO MS; BERG EL, "Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P-selectin", J IMMUNOL., (19980115), vol. 160, no. 2, pages 1029 - 35, XP002959848-
DESCRIPTION- HINTON PR; XIONG JM; JOHLFS MG; TANG MT; KELLER S; TSURUSHITA N., "An engineered human IgGl antibody with longer serum half-life.", J IMMUNOL., (20060101), vol. 176, no. 1, pages 346 - 56-
DESCRIPTION- J. EXP. MED., (1995), vol. 108, page 945-
DESCRIPTION- KASHMIRI SV; SHU L; PADLAN EA; MILENIC DE; SCHLOM J; HAND PH, "Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49", HYBRIDOMA, (199510), vol. 14, no. 5, pages 461 - 73, XP000198397-
DESCRIPTION- KIM SJ; PARK Y; HONG HJ., "Antibody engineering for the development of therapeutic antibodies.", MOL CELLS, (20050831), vol. 20, no. 1, pages 17 - 29, XP055199890-
DESCRIPTION- KIPPS ET AL., J. CLIN. INVEST., (1991), vol. 87, pages 2087 - 2096-
DESCRIPTION- KOBAYASHI H; LE N; KIM IS; KIM MK; PIE JE; DRUMM D; PAIK DS; WALDMANN TA; PAIK CH; CARRASQUILLO JA., "The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points.", CANCER RES., (19990115), vol. 59, no. 2, pages 422 - 30, XP002218244-
DESCRIPTION- K. SATO ET AL., CANCER RES., (1993), vol. 53, pages 851 - 856-
DESCRIPTION- KUNKEL, PROC. NATL. ACAD. SCI. USA, (1985), vol. 82, page 488-
DESCRIPTION- MA ET AL., EUR. J. IMMUNOL., (1994), vol. 24, pages 131 - 138-
DESCRIPTION- MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, pages 581 - 97-
DESCRIPTION- MENDEZ ET AL., NAT. GENET., (1997), vol. 15, pages 146 - 56-
DESCRIPTION- MERCHANT AM ET AL., NATURE BIOTECHNOLOGY, (1998), vol. L6, pages 677 - 681-
DESCRIPTION- MOL. CELL BIOL., (1998), vol. 8, pages 466 - 472-
DESCRIPTION- NAT BIOTECHNOL., (1997), vol. 15, pages 637 - 640-
DESCRIPTION- NIWA ET AL., GENE, (1991), vol. 108, pages 193 - 199-
DESCRIPTION- NIWA ET AL., GENE, (1991), vol. 108, pages 193 - 200-
DESCRIPTION- ONDA M; NAGATA S; TSUTSUMI Y; VINCENT JJ; WANG Q; KREITMAN RJ; LEE B; PASTAN I., "Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity", CANCER RES., (20010701), vol. 61, no. 13, pages 5070 - 7, XP002359466-
DESCRIPTION- ONO K ET AL., MOL IMMUNOL., (199904), vol. 36, no. 6, pages 387 - 395-
DESCRIPTION- PODUSLO JF; CURRAN GL., "olyamine modification increases the permeability of proteins at the blood-nerve and blood-brain barriers.", NEUROCHEM., (199604), vol. 66, no. 4, pages 1599 - 609, XP002943629-
DESCRIPTION- SATO, K. ET AL., CANCER RES., (1993), vol. 53, pages 851 - 856-
DESCRIPTION- SCHAEFFER RC JR; GRATRIX ML; MUCHA DR; CARBAJAL JM., "The rat glomerular filtration barrier does not show negative charge selectivity.", MICROCIRCULATION, (200210), vol. 9, no. 5, pages 329 - 42-
DESCRIPTION- SUSUMU ET AL., NATURE, (1985), vol. 315, pages 592 - 594-
DESCRIPTION- VALLE ET AL., NATURE, (1981), vol. 291, pages 338 - 340-
DESCRIPTION- VAUGHAN ET AL., NATURE BIOTECHNOLOGY, (1996), vol. 14, pages 309 - 14-
DESCRIPTION- WATERHOUSES ET AL., NUCLEIC ACIDS RES., (1993), vol. 21, pages 2265 - 6-
DESCRIPTION- WELSCHOF ET AL., J. IMMUNOL. METHOD, (1995), vol. 179, pages 203 - 214-
DESCRIPTION- YANG K; BASU A; WANG M; CHINTALA R; HSIEH MC; LIU S; HUA J; ZHANG Z; ZHOU J; LI M, "Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation.", PROTEIN ENG., (200310), vol. 6, no. 10, pages 761 - 70, XP003015609-
DESCRIPTION- ZUCKIER LS; CHANG CJ; SCHARFF MD; MORRISON SL., "Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life.", CANCER RES., (19980901), vol. 58, no. 17, pages 3905 - 8, XP002457734-
DESCRIPTION- LOBO ED; HANSEN RJ; BALTHASAR JP, "Antibody pharmacokinetics and pharmacodynamics.", J PHARM SCI., (200411), vol. 93, no. 11, doi:doi:10.1002/jps.20178, pages 2645 - 68, XP008144988
DESCRIPTION- PAVLOU AK; BELSEY MJ., "The therapeutic antibodies market to 2008.", EUR J PHARM BIOPHARM., (200504), vol. 59, no. 3, doi:doi:10.1016/j.ejpb.2004.11.007, pages 389 - 96, XP025317626
DESCRIPTION- EWERT S; HONEGGER A; PLUCKTHUN A., "Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering.", METHODS, (200410), vol. 34, no. 2, doi:doi:10.1016/j.ymeth.2004.04.007, pages 184 - 99, XP004526805
DESCRIPTION- TSURUSHITA N; HINTON PR; KUMAR S., "Design of humanized antibodies: from anti-Tac to Zenapax.", METHODS, (200505), vol. 36, no. 1, doi:doi:10.1016/j.ymeth.2005.01.007, pages 69 - 83, XP004852554
DESCRIPTION- GHETIE V; WARD ES, "FcRn: the MHC class I-related receptor that is more than an IgG transporter", IMMUNOL TODAY, (199712), vol. 18, no. 12, doi:doi:10.1016/S0167-5699(97)01172-9, pages 592 - 8, XP004097421
DESCRIPTION- KIM I; KOBAYASHI H; YOO TM; KIM MK; LE N; HAN ES; WANG QC; PASTAN I; CARRASQUILLO JA; PAIK CH., "Lowering of pI by acylation improves the renal uptake of 99mTc-labeled anti-Tac dsFv: effect of different acylating reagents.", NUCL MED BIOL., (200211), vol. 29, no. 8, doi:doi:10.1016/S0969-8051(02)00341-4, pages 795 - 801 1, XP004395534
DESCRIPTION- PAVLINKOVA G; BERESFORD G; BOOTH BJ; BATRA SK; COLCHER D., "Charge-modified single chain antibody constructs of monoclonal antibody CC49: generation, characterization, pharmacokinetics, and biodistribution analysis.", NUCL MED BIOL., (199901), vol. 26, no. 1, doi:doi:10.1016/S0969-8051(98)00075-4, pages 27 - 34, XP004151297
DESCRIPTION- KIM IS; YOO TM; KOBAYASHI H; KIM MK; LE N; WANG QC; PASTAN I; CARRASQUILLO JA; PAIK CH., "Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-Tac monoclonal antibody labeled with 99mTc.", BIOCONJUG CHEM., (199905), vol. 10, no. 3, doi:doi:10.1021/bc980129m, pages 447 - 53, XP055104433
DESCRIPTION- GHETIE V; POPOV S; BORVAK J; RADU C; MATESOI D; MEDESAN C; OBER RJ; WARD ES, "Increasing the serum persistence of an IgG fragment by random mutagenesis.", NAT BIOTECHNOL., (199707), vol. 15, no. 7, doi:doi:10.1038/nbt0797-637, pages 637 - 40, XP000876642
DESCRIPTION- JANICE M REICHERT; CLARK J ROSENSWEIG; LAURA B FADEN; MATTHEW C DEWITZ, "Monoclonal antibody successes in the clinic", NATURE BIOTECHNOLOGY, (2005), vol. 23, doi:doi:10.1038/nbt0905-1073, pages 1073 - 1078, XP002555770
DESCRIPTION- BINZ HK; AMSTUTZ P; PLUCKTHUN A., "Engineering novel binding proteins from nonimmunoglobulin domains.", NAT BIOTECHNOL., (200510), vol. 23, no. 10, doi:doi:10.1038/nbt1127, pages 1257 - 68, XP002381839
DESCRIPTION- RAJPAL A; BEYAZ N; HABER L; CAPPUCCILLI G; YEE H; BHATT RR; TAKEUCHI T; LERNER RA; CREA R., "A general method for greatly improving the affinity of antibodies by using combinatorial libraries", PROC NATL ACAD SCI U S A., (20050614), vol. 102, no. 24, doi:doi:10.1073/pnas.0503543102, pages 8466 - 71, XP002392777
DESCRIPTION- YAMASAKI Y; SUMIMOTO K; NISHIKAWA M; YAMASHITA F; YAMAOKA K; HASHIDA M; TAKAKURA Y., "harmacokinetic analysis of in vivo disposition of succinylated proteins targeted to liver nonparenchymal cells via scavenger receptors: importance of molecular size and negative charge density for in vivo recognition by receptors.", PHARMACOL EXP THER., (200205), vol. 30I, no. 2, doi:doi:10.1124/jpet.301.2.467, pages 467 - 77, XP003018067
EXAMINATION- M. Josefina Coloma ET AL, "Position Effects of Variable Region Carbohydrate on the Affinity and In Vivo Behavior of an Anti-(1->6) Dextran Antibody", THE JOURNAL OF IMMUNOLOGY, US, (19990215), vol. 162, no. 4, ISSN 0022-1767, page 2162, XP055405539-
EXAMINATION- REIMANN KEITH A ET AL, "A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties", AIDS RESEARCH AND HUMAN RETROVIRU, MARY ANN LIEBERT, US, (19970101), vol. 13, no. 11, ISSN 0889-2229, pages 933 - 943, XP009112647-
EXAMINATION- VERHOEYEN M E ET AL, "Construction of a reshaped HMFG1 antibody and comparison of its fine specificity with that of the parent mouse antibody", IMMUNOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, (19930301), vol. 78, no. 3, ISSN 0019-2805, pages 364 - 370, XP002425226-
EXAMINATION- CAMELLIA W ADAMS ET AL, "Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, (20050903), vol. 55, no. 6, doi:10.1007/S00262-005-0058-X, ISSN 1432-0851, pages 717 - 727, XP019333247
EXAMINATION- LI BOHUA ET AL, "Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions", IMMUNOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 116, no. 4, doi:10.1111/J.1365-2567.2005.02247.X, ISSN 0019-2805, (20051201), pages 487 - 498, (20051007), XP002600947
OPPOSITION- COLOMA M J ET AL, "Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1-->6) dextran antibody.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 FEB 1999 LNKD- PUBMED:9973491, (19990215), vol. 162, no. 4, pages 2162 - 2170, XP002602374-
OPPOSITION- KOBAYASHI H ET AL, "The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points.", Cancer research, American Association for Cancer Research, US, US , (19990115), vol. 59, no. 2, ISSN 0008-5472, pages 422 - 430, XP002218244-
OPPOSITION- ONDA M ET AL, "Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity.", Cancer research, American Association for Cancer Research, US, US , (20010701), vol. 61, no. 13, ISSN 0008-5472, pages 5070 - 5077, XP002359466-
OPPOSITION- Reimann Keith A; Lin Wenyu; Bixler Sarah; Browning Beth; Ehrenfels Barbara N; Lucci Jodie; Miatkowski Konrad; Olson Dian; Parish Thoams H; Rosa Margaret D; Oleson Frederick B; Hsu Yen Ming; Padlan Eduardo A; Letvin Norman L; Burkly Linda C, "A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties", AIDS RESEARCH AND HUMAN RETROVIRUSES., MARY ANN LIEBERT., US, US , (19970101), vol. 13, no. 11, ISSN 0889-2229, pages 933 - 943, XP009112647-
OPPOSITION- Sharifi J; Khawli L A; Hornick J L; Epstein A L, "Improving monoclonal antibody pharmacokinetics via chemical modification", The Quarterly Journal of Nuclear Medicine and Molecular Imaging, Edizioni Minerva Medica, IT, IT , (19980101), vol. 42, no. 4, ISSN 1125-0135, pages 242 - 249, XP009100792-
OPPOSITION- PARDRIDGE WILLIAM M, ET AL, "Enhanced cellular uptake and in vivo biodistribution of a monoclonal antibody following cationization", Journal of Pharmaceutical Sciences, American Chemical Society and American Pharmaceutical Association, US, US , (19950101), vol. 84, no. 8, doi:10.1002/jps.2600840808, ISSN 0022-3549, pages 943 - 948, XP002556033
OPPOSITION- Ryman Josiah T., Meibohm Bernd, "Pharmacokinetics of Monoclonal Antibodies", CPT: Pharmacometrics & Systems Pharmacology, Wiley Blackwell, (20170901), vol. 6, no. 9, doi:10.1002/psp4.12224, ISSN 2163-8306, pages 576 - 588, XP055844575
OPPOSITION- Camellia W. Adams ; David E. Allison ; Kelly Flagella ; Leonard Presta ; Janet Clarke ; Noel Dybdal ; Kathleen McKeever ; Mark X. Sliwkowski, "Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab", Cancer Immunology, Immunotherapy, Springer, Berlin, DE, Berlin, DE , (20060601), vol. 55, no. 6, doi:10.1007/s00262-005-0058-x, ISSN 1432-0851, pages 717 - 727, XP019333247
OPPOSITION- LI BOHUA ET AL, "Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions", Immunology, Wiley-Blackwell Publishing Ltd., GB, GB , (20051201), vol. 116, no. 4, doi:10.1111/J.1365-2567.2005.02247.X, ISSN 0019-2805, pages 487 - 498, XP002600947
OPPOSITION- Isidro Hötzel, Frank-Peter Theil, Lisa J. Bernstein, Saileta Prabhu, Rong Deng, Leah Quintana, Jeff Lutman, Renuka Sibia, Pamela Chan, Daniela Bumbaca, Paul Fielder, Paul J. Carter, Robert F. Kelley, "A strategy for risk mitigation of antibodies with fast clearance", mAbs, Landes Bioscience, US, US , (20121101), vol. 4, no. 6, doi:10.4161/mabs.22189, ISSN 1942-0862, pages 753 - 760, XP055232891
SEARCH- ONDA M ET AL, "Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20010701), vol. 61, no. 13, ISSN 0008-5472, pages 5070 - 5077, XP002359466 [A] 1-15 * page 5076, column l, paragraph 1 *-
SEARCH- ZUCKIER LIONEL S ET AL, "Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD.; US, (19980901), vol. 58, no. 17, ISSN 0008-5472, pages 3905 - 3908, XP002457734 [I] 1,2,7,8,13-15 * abstract * * figures 1,2 * * table 1 *-
SEARCH- PAVLINKOVA G ET AL, "Charge-modified single chain antibody constructs of monoclonal antibody CC49: generation, characterization, pharmacokinetics, and biodistribution analysis - Distribution in normal and tumor-bearing mice", NUCLEAR MEDICINE AND BIOLOGY, ELSEVIER, NY, US, (19990101), vol. 26, no. 1, doi:10.1016/S0969-8051(98)00075-4, ISSN 0969-8051, pages 27 - 34, XP004151297 [A] 1-15 * page 31, column l, paragraph 2 * * figure 5 *
SEARCH- LANCE W L ET AL, "Crystal structure at 2.8 ANG of an FcRn/heterodimeric Fc complex: Mechanism of pH-dependent binding", MOLECULAR CELL, CELL PRESS, CAMBRIDGE, MA, US, (20010401), vol. 7, no. 4, ISSN 1097-2765, pages 867 - 877, XP002305812 [I] 1,2,7,8,13-15 * page 873, column R, paragraph 3 - page 875, column L, paragraph 1 * * table 3 *
SEARCH- GHETIE V ET AL, "INCREASING THE SERUM PERSISTENCE OF AN IGG FRAGMENT BY RANDOM MUTAGENESIS", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, US, (19970101), vol. 15, no. 7, doi:10.1038/NBT0797-637, ISSN 1087-0156, pages 637 - 640, XP000876642 [X] 1,2,7,8,13-15 * abstract * * page 640, column l, paragraph 1 - paragraph 4 * * figure 1 * * table 1 *
SEARCH- SHIELDS R L ET AL, "High resolution mapping of the binding site on human IgG1 for FcgammaRI, FcgammaRII, FcgammaRIII, and FcRn and design of IgG1 variants with improved binding to the FcgammaR", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM, US, (20010302), vol. 276, no. 9, ISSN 0021-9258, pages 6591 - 6604, XP002271092 [I] 1,2,7,8,13-15 * table 1 * * page 6603, column L, paragraph 2 - paragraph 3 *
SEARCH- HINTON PAUL R ET AL, "An engineered human IgG1 antibody with longer serum half-life", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, (20060101), vol. 176, no. 1, ISSN 0022-1767, pages 346 - 356, XP002482524 [X] 1,2,7,8,13-15 * abstract * * page 347, column l, paragraph 2 - column r, paragraph 5 * * figures 2,7 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents